Cochrane · systematic review · CD000222
Ursodeoxycholic acid for cystic fibrosis‐related liver disease
Cheng, K, Ashby, D, Smyth, RL · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 2 · 28.6%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings
Population: adults and children with cystic fibrosis‐related liver disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change of hepatocellular enzymes1 | no estimate extracted | 2 studies · 16 participants | Very low Downgraded: risk of bias, imprecision |
Abnormally large livers reduced to within normal limits, as measured by ultrasound | no estimate extracted | NR | No studies |
Need for liver transplantation | no estimate extracted | 3 studies · 58 participants | Very low Downgraded: risk of bias, imprecision |
Mortality | no estimate extracted | 3 studies · 58 participants | Low Downgraded: risk of bias, imprecision |
Nutritional status: change in weight (kg) | no estimate extracted | 2 studies · 30 participants | Low Downgraded: risk of bias, imprecision |
Development of portal hypertension | no estimate extracted | 2 studies · 30 participants | Low Downgraded: risk of bias, imprecision |
Improved abnormal biliary excretion | no estimate extracted | 1 study · 12 participants | Low Downgraded: risk of bias, imprecision |